Immune oncology in hepatocellular carcinoma—hype and hope

Thus, the definition of a first and so far only standard of care for hepatocellular carcinoma, a milestone 10 years ago, was followed by gridlock; no standard treatment exists for patients with acquired resistance or intolerance to sorafenib.2 However, there is some hope. Another multikinase inhibit...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) Vol. 389; no. 10088; pp. 2448 - 2449
Main Authors:	Wörns, Marcus-Alexander, Galle, Peter R
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 24-06-2017 Elsevier Limited
Subjects:	Antineoplastic Agents - therapeutic use Carcinoma, Hepatocellular - drug therapy Cytotoxicity Drug Resistance, Neoplasm Hepatocellular carcinoma Humans Immunotherapy Inhibitor drugs Internal Medicine Liver cancer Liver Neoplasms - drug therapy Niacinamide - analogs & derivatives Niacinamide - therapeutic use Oncology Patients Phenylurea Compounds - therapeutic use Protein Kinase Inhibitors - therapeutic use Pyridines - therapeutic use Targeted cancer therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Thus, the definition of a first and so far only standard of care for hepatocellular carcinoma, a milestone 10 years ago, was followed by gridlock; no standard treatment exists for patients with acquired resistance or intolerance to sorafenib.2 However, there is some hope. Another multikinase inhibitor, regorafenib, has been shown to significantly improve overall survival of patients after failure of sorafenib-pioneering for the first time systemic second-line therapy in these patients.3
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0140-6736 1474-547X
DOI:	10.1016/S0140-6736(17)31044-9